Replies to post #2221 on Synaptogenix Inc (SNPX)

[SF Wolf]

Antti, thank you for your reasoned and insightful comments. You write:

"But as you probably agree they (NTRP) have actually been very efficient in their execution and are already about to get some definite data from phase 2b. It's not that usual thing in this space IMO and tells how anxious they (and FDA) are to see whether or not this mechanism works."

In your opinion how much input would the FDA have in a study of this importance to the AD research field?